A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

Diabetes Research and Clinical Practice

Volumn 69, Issue 1, 2005, Pages 5-13

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   Gaddi, Antonio ^b   Ragonesi, Pietro D ^c   Piccinni, Mario N ^a   Fogari, Elena ^a   Salvadeo, Sibilla ^a   Ciccarelli, Leonardina ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c S Carlo Hospital   (Italy)

Author keywords

Fibrinolysis; Glimepiride; Metabolic syndrome; Pioglitazone; Rosiglitazone

Indexed keywords

AMINOTRANSFERASE; FIBRINOGEN; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CLOTTING; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART RATE; HEMOGLOBIN DETERMINATION; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD PRESSURE; BODY SIZE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTPRANDIAL PERIOD; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 20444439480     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2004.10.007     Document Type: Article

References (41)

1. G.G. Biondi-Zoccai, A. Abbate, G. Liuzzo, and L.M. Biasucci Atherothrombosis, inflammation, and diabetes J. Am. Coll. Cardiol. 41 7 2003 1071 1077
2. R.D. Abbott, J.D. Curb, and B.L. Rodriguez Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke J. Clin. Epidemiol. 56 5 2003 479 486
3. A.W. Tsai, M. Cushman, W.D. Rosamond, S.R. Heckbert, J.F. Polak, and A.R. Folsom Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology Arch. Intern. Med. 162 10 2002 1182 1189
4. P. Theuma, and V.A. Fonseca Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis Curr. Diab. Rep. 3 3 2003 248 254
5. S. Liu, and W.C. Willett Dietary glycemic load and atherothrombotic risk Curr. Atheroscler. Rep. 4 6 2002 454 461
6. J.E. Reusch Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome Am. J. Cardiol. 90 5A 2002 19G 26G
7. J.P. Tsikouris, J.A. Suarez, and G.E. Meyerrose Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents J. Clin. Pharmacol. 42 11 2002 1187 1199
8. W. Herrmann, and J.P. Knapp Hyperhomocysteinemia: a new risk factor for degenerative diseases Clin. Lab. 48 9-10 2002 471 481
9. K. Ghosh Thrombohaemorrhagic balance in diabetes mellitus J. Indian Med. Assoc. 100 7 2002 428 433
10. D.C. Calverley, M.R. Hacker, and K.A. Loda Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus Br. J. Haematol. 121 1 2003 139 142
11. A. Sambola, J. Osende, and J. Hathcock Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity Circulation 107 7 2003 973 977
12. G. Derosa, Cicero AFG, A. Gaddi, A. Mugellini, L. Ciccarelli, and R. Fogari The effect of l-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus Clin. Ther. 25 5 2003 1429 1439
13. P. Grant Beneficial effects of metformin on haemostasis and vascular function in man Diabetes Metab. 29 4 Pt 2 2003 44 52
14. National Cholesterol Education Program (NCEP) Expert Panel, Summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel III), JAMA 285 (2001) 2486-2497.
15. American Diabetes Association. Screening for diabetes (Position Statement), Diabetes Care 24 (1) (2001) S21-S24.
16. American Diabetes Association, Nutrition recommendations and principles for people with diabetes mellitus (Position Statement), Diabetes Care 24 (1) (2001) S44-S47.
17. D.R. Matthews, J.P. Hosker, and A.S. Rudenski Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
18. H.F. Bunn, H.K. Gabbay, and P.M. Gallop The glycosylation of haemoglobin. Relevance to Diabetes Mellitus Science 200 1978 21 27
19. European Diabetes Policy Group, A desktop guide to type 2 diabetes mellitus, Diab Med 16 (1999) 716-730.
20. L.G. Heding Determination of total serum insulin (IRI) in insulin-treated diabetic patients Diabetologia 8 1972 260 266
21. I. Juhan-Vague, and D. Collen On the role of coagulation and fibrinolysis in atherosclerosis Ann. Epidemiol. 2 1992 427 438
22. A. Clauss Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens Acta Haematol. 17 1959 237 246
23. S. Narayanan Preanalytical aspects of coagulation testing Haematologica 80 2 1995 1 6
24. B.J. Winer Statistical Principles in Experimental Design 2nd ed 1971 McGraw-Hill New York NY
25. American Diabetes Association, American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 25 (1) (2002) S1-S147.
26. G. Charpentier, F. Fleury, M. Kabir, L. Vaur, and S. Halimi Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients Diabet. Med. 18 10 2001 828 834
27. M. Riddle Combining sulfonylureas and other oral agents Am. J. Med. 108 6a 2000 15S 22S
28. A.L. McCall Clinical review of glimepiride Expert Opin. Pharmacother. 2 4 2001 699 713
29. F. Ovalle, and J.F. Ovalle-Berúmen Thiazolidinediones: a review of their benefits and risks South. Med. J. 95 10 2002 1187 1194
30. B.H. Wolffenbuttel, R. Gomis, S. Squatrito, N.P. Jones, and R.N. Patwardhan Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients Diabet. Med. 17 1 2000 40 47
31. V. Vongthavaravat, B.L. Wajchenberg, and J.N. Waitman 125 Study Group, An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes Curr. Med. Res. Opin. 18 8 2002 456 461
32. M. St John Sutton, M. Rendell, and P. Dandona A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes Diabetes Care 25 11 2002 2058 2064
33. I. Pavo, G. Jermendy, and T.T. Varkonyi Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes J. Clin. Endocrinol. Metab. 88 4 2003 1637 1645
34. P.J. Boyle, A.B. King, L. Olansky, A. Marchetti, H. Lau, and R. Magar Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records Clin. Ther. 24 3 2002 378 396
35. M. Massi-Benedetti Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience Clin. Ther. 25 3 2003 799 816
36. R. Weitgasser, M. Lechleitner, A. Luger, and A. Klingler Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study Diabetes Res. Clin. Pract. 61 1 2003 13 19
37. M. Stumvoll, and H.U. Haring Glitazones: clinical effects and molecular mechanisms Ann. Med. 34 3 2002 217 224
38. A.L. Harte, P.G. McTernan, C.L. McTernan, S.A. Smith, A.H. Barnett, and S. Kumar Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes Diabetes Obes. Metab. 5 5 2003 302 310
39. A. Osman, J. Otero, A. Brizolara, S. Waxman, G. Stouffer, and P. Fitzgerald Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes Am. Heart J. 147 5 2004 e23
40. Y. Aso, K.I. Okumura, N. Yoshida, K. Tayama, Y. Takemura, and T. Inukai Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1 Exp. Clin. Endocrinol. Diabetes 112 4 2004 175 180
41. P.J. Grant Beneficial effects of metformin on haemostasis and vascular function in man Diabetes Metab. 29 4 Pt 2 2003 6S44 6S52